Akintunde Olatokumbo Bello - 10 Jun 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director
Signature
/s/ Elana Brockmann, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 16:34:26 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bello Akintunde Olatokumbo Director 828 WINTER STREET, SUITE 300, WALTHAM /s/ Elana Brockmann, Attorney-in-Fact 12 Jun 2025 0002070709

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +62,000 $0.000000 62,000 10 Jun 2025 Common Stock 62,000 $0.7000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on June 10, 2025 and will vest in three equal installments on June 10, 2026, June 10, 2027 and June 10, 2028, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.